Packaging and Uncoating of CRISPR/Cas Ribonucleoproteins for Efficient Gene Editing with Viral and Non-Viral Extracellular Nanoparticles

Viruses. 2023 Mar 6;15(3):690. doi: 10.3390/v15030690.

Abstract

Rapid progress in gene editing based on clustered regularly interspaced short palindromic repeats/CRISPR-associated protein (CRISPR/Cas) has revolutionized functional genomic studies and genetic disease correction. While numerous gene editing applications have been easily adapted by experimental science, the clinical utility of CRISPR/Cas remains very limited due to difficulty in delivery to primary cells and possible off-target effects. The use of CRISPR in the form of a ribonucleoprotein (RNP) complex substantially reduces the time of DNA exposure to the effector nuclease and minimizes its off-target activity. The traditional electroporation and lipofection methods lack the cell-type specificity of RNP delivery, can be toxic for cells, and are less efficient when compared to nanoparticle transporters. This review focuses on CRISPR/Cas RNP packaging and delivery using retro/lentiviral particles and exosomes. First, we briefly describe the natural stages of viral and exosomal particle formation, release and entry into the target cells. This helps us understand the mechanisms of CRISPR/Cas RNP packaging and uncoating utilized by the current delivery systems, which we discuss afterward. Much attention is given to the exosomes released during viral particle production that can be passively loaded with RNPs as well as the mechanisms necessary for particle fusion, RNP release, and transportation inside the target cells. Collectively, together with specific packaging mechanisms, all these factors can substantially influence the editing efficiency of the system. Finally, we discuss ways to improve CRISPR/Cas RNP delivery using extracellular nanoparticles.

Keywords: CRISPR; Cas9 ribonucleoprotein; HIV assembly and disassembly; delivery; exosomes; virus-like particles.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • CRISPR-Cas Systems
  • DNA / metabolism
  • Gene Editing* / methods
  • Nanoparticles*
  • Ribonucleoproteins / genetics
  • Ribonucleoproteins / metabolism

Substances

  • Ribonucleoproteins
  • DNA

Grants and funding

This research was funded by the Russian Science Foundation, grant number 22-15-00381, and by the Ministry of Science and Higher Education of the Russian Federation, grant number 075-15-2019-1661.